AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Shares outstanding
AbbVie Inc.'s shares outstanding at the end of fiscal 2025 was $1.8B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.8B. Over the past ten years it has ranged from $1.5B (fiscal 2019) to $1.8B (fiscal 2022); the current reading is higher than 82% of that period. AbbVie Inc. ranks 9th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $1.8B | 0.00% |
| FY2024 | $1.8B | 0.00% |
| FY2023 | $1.8B | (0.28%) |
| FY2022 | $1.8B | 0.06% |
| FY2021 | $1.8B | 6.22% |
| FY2020 | $1.7B | 12.74% |
| FY2019 | $1.5B | (4.01%) |
| FY2018 | $1.5B | (3.56%) |
| FY2017 | $1.6B | (1.72%) |
| FY2016 | $1.6B | (0.37%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $1.8B | (0.17%) |
| Mar 2026 | $1.8B | 0.06% |
| Dec 2025 | $1.8B | 0.06% |
| Sep 2025 | $1.8B | 0.06% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.7B |
| MRK Merck & Co., Inc. compare | $2.5B |
| JNJ Johnson & Johnson compare | $2.4B |
| NVS Novartis AG compare | $1.9B |
| ABBV AbbVie Inc. | $1.8B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.2B |
| LLY Eli Lilly and Company compare | $893.7M |
| AMGN Amgen Inc. compare | $544.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement